Press release

Almirall invests in AB-Biotics to strengthen the pharmacogenetics area
Barcelona, 23 October 2012.- Almirall (ALM.MC), the international pharmaceutical company headquarted in Barcelona, has reached an agreement with the Spanish biotech company AB-Biotics (ABB.MC) to enter the share capital of the company listed on the Spanish Alternative Investment Market (MAB).
Almirall becoming part of the share capital of AB-Biotics will enhance the commercial expansion of the pharmacogenetics tests developed by the biotech company. Both companies will be working together on the promotion and commercialisation of Neurofarmagen in Spain from 2013. It is a genetic test that uses DNA extracted from a saliva sample to enable the doctor to identify a patient’s predilection to respond to the most commonly used active principles in the treatment of depression, schizophrenia, bipolar disorder and epilepsy.

The operation will become effective by the subscription by Almirall of 465,115 shares from AB-Biotics, at a value of 2.15 euros per share, as part of the share capital increase that AB-Biotics currently holds open in the MAB and guarantees a minimum shareholding of 5%. This capital will go towards financing studies and research programmes in AB-Biotics’s genetics area, and the international expansion of products in this area.

This operation enables Almirall to complement its commitment to innovation through pharmacogenetics and personalised medicine, one of the specialist areas of AB-Biotics.

"The entry of Almirall is an important boost for the capital increase has AB-Biotics is currently open -said Miquel Angel Bonachera and Sergi Audivert, co-founders and CEOs of AB-Biotic-. It is also an example of the growing need of alliances between biotechnology and pharmaceutical companies to promote innovation in health, and this alliance will take our pharmacogenetic tests to a wider audience. "

Developed by Web4Bio